BRIEF—Prevail raises $50 million

Prevail Therapeutics has raised $50 million in a series B financing round. The company is focused on developing AAV-based gene therapies for neurodegenerative disorders.

The money will be used to advance pipeline development. With this financing, Prevail has raised approximately $129 million to date.

Chief executive Asa Abeliovich said: “The support of our robust group of investors will enable the advancement of our programs and the growth of our team as we transition into a clinical stage company.”